comprehensive -WSS

comprehensive

author：explore 2025-08-07 16:19:06 - browse：458

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Scientists unlock the key to scar

entertainment

WSS

Weight loss drugs should be covered by insurers, AMA says

Kenai launches with $82 million for Parkinson’s stem cell therapy

Congress gives doctors Medicare pay bump

Publishing genetic code of viruses could cause disaster

Type 2 diabetes prevention programs work at large scale: study

FogPharma raises $145 million in rare Series E round

focus

comprehensive

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

House looks to weaken Medicare negotiation

Jerome Adams on the need for new antivirals for Covid

Publishing genetic code of viruses could cause disaster

In age of alternative facts, a scholarly course on calling out crap

Biotech companies concerned about China biosecurity crackdown

23andMe had bad news about my health. I wish a person had delivered it

How to fix the rural physician shortage in the U.S.

At least 13 dead in Texas as scorching temps continue

Today's health inequities arise from racist U.S. history, say experts

hotspot

Medical school prerequisites are outdated

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

RaDonda Vaught to speak at CommonSpirit event on patient safety

Pfizer highlights cancer drugs it thinks could reignite investor interest

Obesity now affects over 1 billion people worldwide, study finds

How to fix the rural physician shortage in the U.S.

explore

entertainment

knowledge

focus